4 terminated, 3 recruiting, 1 active not recruiting, 1 completed. 8 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Terminated 4, Recruiting 2, Completed 1, Withdrawn 1 |
| Phase 2 | 7 | Terminated 3, Active not recruiting 1, Completed 1, Recruiting 1, Withdrawn 1 |
Follow NextCure, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer Oxaliplatin, Irinotecan, Folinic Acid - Pancreatic Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 20 | 2025-09-04 | 2026-05-05 |
| A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors SIM0505 for injection - Advanced Solid Tumors, Platinum Resistant Ovarian Cancer | Phase 1 | Recruiting | NextCure, Inc. | 738 | 2025-02-26 | 2026-08-17 |
| A Phase 1 Study of LNCB74 in Advanced Solid Tumors LNCB74 - Ovarian Cancer, Breast Cancer | Phase 1 | Recruiting | NextCure, Inc. | 145 | 2025-01-07 | 2026-08-21 |
| A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms NC525 - Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia | Phase 1 | Terminated | NextCure, Inc. | 28 | 2023-02-28 | 2026-01-28 |
| A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors NC410, pembrolizumab - Advanced or Metastatic Solid Tumors, Microsatellite Instability Low | Phase 1 / Phase 2 | Terminated | NextCure, Inc. | 97 | 2022-10-06 | 2026-08-13 |
| A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC NC318, Pemetrexed/Carboplatin, Nab paclitaxel/Carboplatin - Advanced or Metastatic Solid Tumors, Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Withdrawn | NextCure, Inc. | 2021-12-06 | 2021-08-18 | |
| A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors NC762 - Advanced or Metastatic Solid Tumors, Ovarian Cancer | Phase 1 / Phase 2 | Terminated | NextCure, Inc. | 40 | 2021-06-30 | 2025-04-22 |
| The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer NC318 800 mg, NC318 400 mg, Pembrolizumab - Advanced Non-small Cell Lung Cancer | Phase 2 | Active not recruiting | Yale University | 159 | 2021-02-04 | 2026-08-21 |
| A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors NC410 - Advanced or Metastatic Solid Tumors, Ovarian Cancer | Phase 1 / Phase 2 | Terminated | NextCure, Inc. | 46 | 2020-06-10 | 2024-07-25 |
| A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors NC318 - Advanced or Metastatic Solid Tumors, Lung Cancer | Phase 1 / Phase 2 | Completed | NextCure, Inc. | 109 | 2018-10-01 | 2024-03-08 |
Neoplasm Metastasis (5) · Carcinoma, Non-Small-Cell Lung (4) · Ovarian Neoplasms (4) · Breast Neoplasms (3) · Endometrial Neoplasms (3) · Lung Neoplasms (3) · Colonic Neoplasms (2) · Stomach Neoplasms (2) · Biliary Tract Neoplasms (1) · Carcinoma (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Cholangiocarcinoma (1) · Esophageal Neoplasms (1) · Fallopian Tube Neoplasms (1)
pembrolizumab (2) · Carboplatin (1) · Docetaxel (1) · Fluorouracil (1) · Injections (1) · Ipilimumab (1) · Irinotecan (1) · Leucovorin (1) · Nivolumab (1) · Oxaliplatin (1) · Pemetrexed (1) · Taxes (1)
United States (9) · China (1)
Han Myint, MD (4) · Katherine Bever, MD (1) · Scott Gettinger (1) · Sol Langermann, PhD (1) · Udayan Guha, MD (1)
P50CA196530 (1)